Neuroleptic malignant syndrome in Huntington disease
European Journal of Neurology · 2024
DOI: 10.1111/ene.16442 ↗At a glance
Fallbericht in European Journal of Neurology, 2024. Written by Antonio Funcis and 6 co-authors. Institution: Institute of Neurology, Catholic University of the Sacred Heart, Rome, Italy. Major MEDLINE topics: Huntington Disease, Neuroleptic Malignant Syndrome. Cited 2 times so far (Crossref); 31 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
Background and Purpose Despite the wide use of dopamine receptor blocking agents (DRBAs) in Huntington disease (HD), neuroleptic malignant syndrome (NMS) is rarely described in this population. The aim of this study was to assess NMS prevalence in a large cohort of HD patients and explore the main associated risk factors.
Methods
In 2023, an HD patient was admitted to our neurology department due to NMS. Starting from the case description, we performed a narrative review of the literature of NMS cases in HD, reviewed data from the fifth dataset of the Enroll‐HD (a longitudinal, observational, global study of families with HD) study (PDS5) selecting HD patients treated with DRBAs and/or tetrabenazine (TBZ) who presented at least one of the core symptoms of NMS (rigidity and hyperthermia), and collected data to investigate prevalence of NMS and identify risk factors.
Results
In the Enroll‐HD PDS5 dataset, we identified 5108 of 11,569 HD patients who were undergoing DRBA and/or TBZ treatment. Only one patient, a Caucasian man of 46 years, undergoing clozapine and valproate treatment, had a registered diagnosis of NMS.
Conclusions
NMS in HD patients is seldom described. This could be due to an underestimation of this condition. There are no available objective NMS diagnostic criteria at present, and the existence of atypical forms of NMS further complicates diagnosis. Advanced disease stage, rigid–akinetic phenotype, abrupt therapy changes, polytherapy, and dehydration are key risk factors, most of which are preventable through awareness and caution in managing medications in the HD population.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Institute of Neurology, Catholic University of the Sacred Heart, Rome, Italy.
- Institute of Neurology, Policlinic A. Gemelli Foundation, Rome, Italy.
ORCID profiles: Antonio Funcis
Cite
APA
Funcis, A., Ravera, B., Zinzi, P., Solito, M., Petracca, M., Calabresi, P., & Bentivoglio, A. R. (2024). Neuroleptic malignant syndrome in Huntington disease. European Journal of Neurology. https://doi.org/10.1111/ene.16442
Vancouver
Funcis A, Ravera B, Zinzi P, Solito M, Petracca M, Calabresi P, et al. Neuroleptic malignant syndrome in Huntington disease. European Journal of Neurology. 2024. doi:10.1111/ene.16442
BibTeX
@article{Funcis2024,
author = {Funcis, Antonio and Ravera, Beatrice and Zinzi, Paola and Solito, Marcella and Petracca, Martina and Calabresi, Paolo and Bentivoglio, Anna Rita},
title = {Neuroleptic malignant syndrome in Huntington disease},
journal = {European Journal of Neurology},
year = {2024},
doi = {10.1111/ene.16442}
}
EUVIMED